Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 5
2018 4
2019 9
2020 7
2021 12
2022 5
2023 20
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Alcohol use disorder among people diagnosed with tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and challenges to treatment adherence.
Bayigga J, Kakai I, Odongpiny EAL, Ddungu A, Semakula L, Nansereko M, Wiltshire CS, Stavia T, Zawedde-Muyanja S. Bayigga J, et al. Among authors: wiltshire cs. Subst Abuse Treat Prev Policy. 2025 Mar 5;20(1):10. doi: 10.1186/s13011-024-00629-3. Subst Abuse Treat Prev Policy. 2025. PMID: 40045303 Free PMC article.
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol.
Sekaggya-Wiltshire C, Mbabazi I, Nabisere RM, Alinaitwe L, Otaalo B, Aber F, Nampala J, Owori R, Bayigga J, Mayito J, Banturaki G, Laker EAO, Castelnuovo B, Sekadde MP, Pasipanodya J, Dooley KE, Stavia T, Zawedde-Muyanja S. Sekaggya-Wiltshire C, et al. BMJ Open. 2024 Dec 31;14(12):e088389. doi: 10.1136/bmjopen-2024-088389. BMJ Open. 2024. PMID: 39740953 Free PMC article.
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.
Asiimwe IG, Blockman M, Cavallari LH, Cohen K, Cupido C, Dandara C, Davis BH, Jacobson B, Johnson JA, Lamorde M, Limdi NA, Morgan J, Mouton JP, Muyambo S, Nakagaayi D, Ndadza A, Okello E, Perera MA, Schapkaitz E, Sekaggya-Wiltshire C, Semakula JR, Tatz G, Waitt C, Yang G, Zhang EJ, Jorgensen AL, Pirmohamed M. Asiimwe IG, et al. Among authors: sekaggya wiltshire c. Blood Adv. 2024 Oct 22;8(20):5248-5261. doi: 10.1182/bloodadvances.2024014227. Blood Adv. 2024. PMID: 39163621 Free PMC article.
Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol.
Sekaggya-Wiltshire C, Mbabazi I, Nabisere-Arinaitwe R, Banturaki G, Alinaitwe L, Otalo B, Aber F, Nampala J, Owor R, Bayiga J, Laker Agnes Odongpiny E, Castelnuovo B, Mayito J, Sekadde M, Pasipanodya JG, Turyahabwe S, Zawedde-Muyanja S. Sekaggya-Wiltshire C, et al. medRxiv [Preprint]. 2024 Jun 2:2024.06.01.24308310. doi: 10.1101/2024.06.01.24308310. medRxiv. 2024. Update in: BMJ Open. 2024 Dec 31;14(12):e088389. doi: 10.1136/bmjopen-2024-088389. PMID: 38853861 Free PMC article. Updated. Preprint.
Tuberculosis and diabetes mellitus comorbidity in an adult Ugandan population.
Kibirige D, Andia-Biraro I, Olum R, Adakun S, Zawedde-Muyanja S, Sekaggya-Wiltshire C, Kimuli I. Kibirige D, et al. Among authors: sekaggya wiltshire c. BMC Infect Dis. 2024 Feb 22;24(1):242. doi: 10.1186/s12879-024-09111-8. BMC Infect Dis. 2024. PMID: 38389045 Free PMC article.
"It is not easy": Experiences of people living with HIV and tuberculosis on Tuberculosis treatment in Uganda.
Nabisere-Arinaitwe R, Namatende-Sakwa L, Bayiga J, Nampala J, Alinaitwe L, Aber F, Otaalo B, Musaazi J, King R, Kesby M, Sloan DJ, Sekaggya-Wiltshire C. Nabisere-Arinaitwe R, et al. Among authors: sekaggya wiltshire c. J Clin Tuberc Other Mycobact Dis. 2023 Jun 21;33:100385. doi: 10.1016/j.jctube.2023.100385. eCollection 2023 Dec. J Clin Tuberc Other Mycobact Dis. 2023. PMID: 38116575 Free PMC article.
Monocyte to Lymphocyte ratio is highly specific in diagnosing latent tuberculosis and declines significantly following tuberculosis preventive therapy: A cross-sectional and nested prospective observational study.
Mayito J, Meya DB, Miriam A, Dhikusooka F, Rhein J, Sekaggya-Wiltshire C. Mayito J, et al. Among authors: sekaggya wiltshire c. PLoS One. 2023 Nov 30;18(11):e0291834. doi: 10.1371/journal.pone.0291834. eCollection 2023. PLoS One. 2023. PMID: 38033005 Free PMC article.
Target product profiles: tests for tuberculosis treatment monitoring and optimization.
Gupta-Wright A, den Boon S, MacLean EL, Cirillo D, Cobelens F, Gillespie SH, Kohli M, Ruhwald M, Savic R, Brigden G, Gidado M, Goletti D, Hanna D, Hasan R, Hewison C, Koura KG, Lienhardt C, Lungu P, McHugh TD, McKenna L, Scott C, Scriba T, Sekaggya-Wiltshire C, Kasaeva T, Zignol M, Denkinger CM, Falzon D. Gupta-Wright A, et al. Among authors: sekaggya wiltshire c. Bull World Health Organ. 2023 Nov 1;101(11):730-737. doi: 10.2471/BLT.23.290901. Epub 2023 Oct 4. Bull World Health Organ. 2023. PMID: 37961060 Free PMC article.
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Kengo A, et al. Among authors: sekaggya wiltshire c. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043023. doi: 10.1128/aac.00430-23. Epub 2023 Oct 18. Antimicrob Agents Chemother. 2023. PMID: 37850738 Free PMC article. Clinical Trial.
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
Kengo A, Gausi K, Nabisere R, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Sekaggya-Wiltshire C, Denti P. Kengo A, et al. Among authors: sekaggya wiltshire c. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043123. doi: 10.1128/aac.00431-23. Epub 2023 Oct 18. Antimicrob Agents Chemother. 2023. PMID: 37850737 Free PMC article.
Perspectives of people living with HIV on barriers to timely ART initiation following referral for antiretroviral therapy: A qualitative study at an urban HIV clinic in Kampala, Uganda.
Kiyingi M, Nankabirwa JI, Wiltshire CS, Nangendo J, Kiweewa JM, Katahoire AR, Semitala FC. Kiyingi M, et al. Among authors: wiltshire cs. PLOS Glob Public Health. 2023 Jul 26;3(7):e0001483. doi: 10.1371/journal.pgph.0001483. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37494338 Free PMC article.
A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study.
Jorgensen AL, Orrell C, Waitt C, Toh CH, Sekaggya-Wiltshire C, Hughes DA, Allen E, Okello E, Tatz G, Culeddu G, Asiimwe IG, Semakula JR, Mouton JP, Cohen K, Blockman M, Lamorde M, Pirmohamed M. Jorgensen AL, et al. Among authors: sekaggya wiltshire c. JMIR Res Protoc. 2023 Jul 19;12:e46710. doi: 10.2196/46710. JMIR Res Protoc. 2023. PMID: 37467034 Free PMC article.
A commentary on establishing a local centre of excellence for research and training in pharmacometrics: Lessons from the pharmacometrics Africa-Uganda chapter.
Najjemba L, Kawuma AN, Ojara FW, Obura B, Sekaggya-Wiltshire C, Arinaitwe W, Kikonyogo R, Mukonzo J, Pillai GC, Waitt C. Najjemba L, et al. Among authors: sekaggya wiltshire c. Br J Clin Pharmacol. 2023 Sep;89(9):2658-2661. doi: 10.1111/bcp.15832. Epub 2023 Jul 7. Br J Clin Pharmacol. 2023. PMID: 37417585 Free PMC article. No abstract available.
Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017-2019.
Ssendikwanawa E, Juniour Nsubuga E, Lee S, Frances Zalwango J, Joan Bayowa R, Judith Ssemasaazi A, Ronald Muganga K, Adolphus C, Akunzirwe R, Nante Wangi R, Ronald Kasoma M, Kalyango JN, Karamagi C, Sekaggya-Wiltshire C. Ssendikwanawa E, et al. Among authors: sekaggya wiltshire c. J Clin Tuberc Other Mycobact Dis. 2023 Jan 24;31:100349. doi: 10.1016/j.jctube.2023.100349. eCollection 2023 May. J Clin Tuberc Other Mycobact Dis. 2023. PMID: 37181458 Free PMC article.
Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda.
Omali D, Buzibye A, Kwizera R, Byakika-Kibwika P, Namakula R, Matovu J, Mbabazi O, Mande E, Sekaggya-Wiltshire C, Nakanjako D, Gutteck U, McAdam K, Easterbrook P, Kambugu A, Fehr J, Castelnuovo B, Manabe YC, Lamorde M, Mueller D, Merry C. Omali D, et al. Among authors: sekaggya wiltshire c. Afr J Lab Med. 2023 Feb 7;12(1):1956. doi: 10.4102/ajlm.v12i1.1956. eCollection 2023. Afr J Lab Med. 2023. PMID: 36873289 Free PMC article.
Increased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in Uganda.
Musaazi J, Sekaggya-Wiltshire C, Okoboi S, Zawedde-Muyanja S, Senkoro M, Kalema N, Kavuma P, Namuwenge PM, Manabe YC, Castelnuovo B, Kiragga A. Musaazi J, et al. Among authors: sekaggya wiltshire c. PLoS One. 2023 Feb 23;18(2):e0268935. doi: 10.1371/journal.pone.0268935. eCollection 2023. PLoS One. 2023. PMID: 36821550 Free PMC article.
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM; TRUNCATE-TB Trial Team. Paton NI, et al. Among authors: sekaggya wiltshire c. N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20. N Engl J Med. 2023. PMID: 36808186 Free PMC article. Clinical Trial.
Prospective evaluation of radiographic manifestations of tuberculosis in relationship with CD4 count in patients with HIV/AIDS.
Frey V, Phi Van VD, Fehr JS, Ledergerber B, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Bauer M, Eberhard N, Martini K, Frauenfelder T. Frey V, et al. Among authors: sekaggya wiltshire c. Medicine (Baltimore). 2023 Feb 17;102(7):e32917. doi: 10.1097/MD.0000000000032917. Medicine (Baltimore). 2023. PMID: 36800631 Free PMC article.
The Impact of Chronic Pulmonary Aspergillosis Co-infection on the Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Uganda.
Namusobya M, Bongomin F, Mukisa J, Batte C, Olwit WK, Rhein J, Sekaggya-Wiltshire C, Prasad S. Namusobya M, et al. Among authors: sekaggya wiltshire c. Res Sq [Preprint]. 2023 Jan 13:rs.3.rs-2389854. doi: 10.21203/rs.3.rs-2389854/v1. Res Sq. 2023. Update in: Mycopathologia. 2023 Oct;188(5):713-720. doi: 10.1007/s11046-023-00741-1. PMID: 36711486 Free PMC article. Updated. Preprint.
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.
Asiimwe IG, Blockman M, Cohen K, Cupido C, Hutchinson C, Jacobson B, Lamorde M, Morgan J, Mouton JP, Nakagaayi D, Okello E, Schapkaitz E, Sekaggya-Wiltshire C, Semakula JR, Waitt C, Zhang EJ, Jorgensen AL, Pirmohamed M. Asiimwe IG, et al. Among authors: sekaggya wiltshire c. Front Pharmacol. 2022 Sep 23;13:967082. doi: 10.3389/fphar.2022.967082. eCollection 2022. Front Pharmacol. 2022. PMID: 36210801 Free PMC article.
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, Aber F, Alinaitwe L, Nampala J, Najjemba L, Buzibye A, Omali D, Gausi K, Kengo A, Lamorde M, Aarnoutse R, Denti P, Dooley KE, Sloan DJ. Sekaggya-Wiltshire C, et al. Clin Infect Dis. 2023 Feb 8;76(3):e910-e919. doi: 10.1093/cid/ciac585. Clin Infect Dis. 2023. PMID: 35861296 Free PMC article. Clinical Trial.
Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
Romo ML, Brazier E, Mahambou-Nsondé D, De Waal R, Sekaggya-Wiltshire C, Chimbetete C, Muyindike WR, Murenzi G, Kunzekwenyika C, Tiendrebeogo T, Muhairwe JA, Lelo P, Dzudie A, Twizere C, Rafael I, Ezechi OC, Diero L, Yotebieng M, Fenner L, Wools-Kaloustian KK, Shah NS, Nash D; International epidemiology Databases to Evaluate AIDS (IeDEA). Romo ML, et al. Among authors: sekaggya wiltshire c. J Int AIDS Soc. 2022 Jul;25(7):e25961. doi: 10.1002/jia2.25961. J Int AIDS Soc. 2022. PMID: 35848120 Free PMC article.
Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm.
Asiimwe IG, Blockman M, Cohen K, Cupido C, Hutchinson C, Jacobson B, Lamorde M, Morgan J, Mouton JP, Nakagaayi D, Okello E, Schapkaitz E, Sekaggya-Wiltshire C, Semakula JR, Waitt C, Zhang EJ, Jorgensen AL, Pirmohamed M. Asiimwe IG, et al. Among authors: sekaggya wiltshire c. CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):20-29. doi: 10.1002/psp4.12740. Epub 2021 Dec 9. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34889080 Free PMC article.
Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
Byakika-Kibwika P, Sekaggya-Wiltshire C, Semakula JR, Nakibuuka J, Musaazi J, Kayima J, Sendagire C, Meya D, Kirenga B, Nanzigu S, Kwizera A, Nakwagala F, Kisuule I, Wayengera M, Mwebesa HG, Kamya MR, Bazeyo W. Byakika-Kibwika P, et al. Among authors: sekaggya wiltshire c. BMC Infect Dis. 2021 Dec 6;21(1):1218. doi: 10.1186/s12879-021-06897-9. BMC Infect Dis. 2021. PMID: 34872511 Free PMC article. Clinical Trial.
One dollar incentive improves tuberculosis treatment outcomes in programmatic settings in rural Uganda.
Baluku JB, Nakazibwe B, Twinomugisha B, Najjuuko R, Isabella N, Nassozi S, Namiiro S, Katagira W, Byonanebye DM, Sekaggya-Wiltshire C, Muchiri J, Ndungu E, Anguzu G, Mayanja-Kizza H, Andia-Biraro I. Baluku JB, et al. Among authors: sekaggya wiltshire c. Sci Rep. 2021 Sep 29;11(1):19346. doi: 10.1038/s41598-021-98770-7. Sci Rep. 2021. PMID: 34588552 Free PMC article. Clinical Trial.
Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.
Namugenyi J, Musaazi J, Katamba A, Kalyango J, Sendaula E, Kambugu A, Fehr J, Castelnouvo B, Manabe YC, Ssengooba W, Sekaggya-Wiltshire C. Namugenyi J, et al. Among authors: sekaggya wiltshire c. BMC Infect Dis. 2021 Jun 1;21(1):513. doi: 10.1186/s12879-021-06220-6. BMC Infect Dis. 2021. PMID: 34074248 Free PMC article.
Internal Medicine Clerkship Amidst COVID-19 Pandemic: A Cross-Sectional Study of the Clinical Learning Experience of Undergraduate Medical Students at Makerere University, Uganda.
Bongomin F, Olum R, Nakiyingi L, Lalitha R, Ssinabulya I, Sekaggya-Wiltshire C, Ocama P, Byakika-Kibwika P. Bongomin F, et al. Among authors: sekaggya wiltshire c. Adv Med Educ Pract. 2021 Mar 12;12:253-262. doi: 10.2147/AMEP.S300265. eCollection 2021. Adv Med Educ Pract. 2021. PMID: 33746525 Free PMC article.
MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection.
Rupprechter SAE, Sloan DJ, Oosthuyzen W, Bachmann TT, Hill AT, Dhaliwal K, Templeton K, Matovu J, Sekaggya-Wiltshire C, Dear JW. Rupprechter SAE, et al. Among authors: sekaggya wiltshire c. Br J Clin Pharmacol. 2021 Aug;87(8):3206-3217. doi: 10.1111/bcp.14736. Epub 2021 Jan 26. Br J Clin Pharmacol. 2021. PMID: 33432705 Free PMC article.
Sensitivity and specificity of the mean corpuscular volume and CD4/CD8 ratio in discriminating between rifampicin resistant and rifampicin sensitive tuberculosis.
Baruch Baluku J, Musaazi J, Mulwana R, Bengo D, Sekaggya Wiltshire C, Andia-Biraro I. Baruch Baluku J, et al. Among authors: sekaggya wiltshire c. J Clin Tuberc Other Mycobact Dis. 2020 Nov 23;21:100205. doi: 10.1016/j.jctube.2020.100205. eCollection 2020 Dec. J Clin Tuberc Other Mycobact Dis. 2020. PMID: 33294630 Free PMC article.
Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda.
Asiimwe IG, Waitt C, Sekaggya-Wiltshire C, Hutchinson C, Okello E, Zhang EJ, Semakula JR, Mouton JP, Cohen K, Blockman M, Lamorde M, Jorgensen AL, Pirmohamed M. Asiimwe IG, et al. Among authors: sekaggya wiltshire c. Clin Pharmacol Ther. 2021 Jun;109(6):1564-1574. doi: 10.1002/cpt.2128. Epub 2020 Dec 28. Clin Pharmacol Ther. 2021. PMID: 33280090
Optimal therapy for multidrug-resistant tuberculosis and HIV.
Mayanja-Kizza H, Sekaggya-Wiltshire C, Kassa D. Mayanja-Kizza H, et al. Among authors: sekaggya wiltshire c. Lancet. 2020 Aug 8;396(10248):363-365. doi: 10.1016/S0140-6736(20)31688-3. Lancet. 2020. PMID: 32771093 No abstract available.
Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?".
Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Sekaggya-Wiltshire C, et al. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 32209563 Free PMC article. No abstract available.
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C. Nabisere R, et al. Among authors: sekaggya wiltshire c. Trials. 2020 Feb 13;21(1):181. doi: 10.1186/s13063-020-4132-7. Trials. 2020. PMID: 32054536 Free PMC article.
A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa.
Semakula JR, Mouton JP, Jorgensen A, Hutchinson C, Allie S, Semakula L, French N, Lamorde M, Toh CH, Blockman M, Sekaggya-Wiltshire C, Waitt C, Pirmohamed M, Cohen K. Semakula JR, et al. Among authors: sekaggya wiltshire c. PLoS One. 2020 Jan 29;15(1):e0227458. doi: 10.1371/journal.pone.0227458. eCollection 2020. PLoS One. 2020. PMID: 31995565 Free PMC article.
Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.
Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B. Buzibye A, et al. Among authors: sekaggya wiltshire c. AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x. AIDS Res Ther. 2019. PMID: 31810468 Free PMC article.
Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?
Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Sekaggya-Wiltshire C, et al. Antimicrob Agents Chemother. 2019 May 24;63(6):e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30910890 Free PMC article.
A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients.
Kaboggoza JP, Wang X, Neary M, Ayuso P, Sekaggya-Wiltshire C, Nakalema S, Owen A, McClure M, Lamorde M, Boffito M. Kaboggoza JP, et al. Among authors: sekaggya wiltshire c. Open Forum Infect Dis. 2019 Jan 16;6(2):ofz035. doi: 10.1093/ofid/ofz035. eCollection 2019 Feb. Open Forum Infect Dis. 2019. PMID: 30815503 Free PMC article. No abstract available.
Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.
Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, Ssemwanga D, Fehr J, Castelnuovo B, Sekaggya-Wiltshire C, von Braun A. Baumann A, et al. Among authors: sekaggya wiltshire c. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943. J Acquir Immune Defic Syndr. 2019. PMID: 30633041 Free article.
Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.
Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study. Bachmann N, et al. Among authors: sekaggya wiltshire c. J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436. J Antimicrob Chemother. 2019. PMID: 30476115
Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort.
Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kamya M, Castelnuovo B. Weissberg D, et al. Among authors: sekaggya wiltshire c. PLoS One. 2018 Nov 1;13(11):e0206796. doi: 10.1371/journal.pone.0206796. eCollection 2018. PLoS One. 2018. PMID: 30383836 Free PMC article.
HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.
von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A. von Braun A, et al. Among authors: sekaggya wiltshire c. J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717. J Acquir Immune Defic Syndr. 2018. PMID: 29771783 Free article.
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS. Sekaggya-Wiltshire C, et al. Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179. Clin Infect Dis. 2018. PMID: 29514175 Free PMC article. Clinical Trial.
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A. Sekaggya-Wiltshire C, et al. BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679. BMJ Open. 2017. PMID: 28928173 Free PMC article.
Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda.
Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, Nakijoba R, Nalwanga D, Henning L, Von Braun A, Okware S, Castelnuovo B, Kambugu A, Fehr J. Wiltshire CS, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19585. doi: 10.7448/IAS.17.4.19585. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394091 Free PMC article.